Graft-versus-host disease
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease |
|
Risk calculators and risk factors for Graft-versus-host disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: GVHD
Overview
Graft-versus-host disease (GvHD) is a condition characterized by recipient tissue damage that arise from immunological activation of donor T lymphocytes. It typically occurs in the setting of bone marrow transplantation. Donor T cells mount a response against foreign host cells in the gastrointestinal system, liver, and skin.
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Graft-versus-host disease from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies
Treatment
[[Graft-versus-host disease medical therapy |Medical Therapy]]
The treatment of GvHD focuses on immunosuppression. Immunosuppression is usually achieved by administering steroids, auch as prednisone or methylprednisolone.[1] Alternative agents include immunophilins like cyclosporine or tacrolimus.[1] Ruxolitinib has been used for GvHD that is refractory to steroids.[2]
| Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters
- ↑ 1.0 1.1 Jacobsohn DA, Vogelsang GB (2007). "Acute graft versus host disease". Orphanet J Rare Dis. 2: 35. doi:10.1186/1750-1172-2-35. PMC 2018687. PMID 17784964.
- ↑ Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B (2017). "Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease". Br J Haematol. doi:10.1111/bjh.14679. PMID 28444730.